Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | CoVasc-ICH: assessing colchicine as a treatment for ICH

Aristeidis Katsanos, MD, PhD, McMaster University, Hamilton, Ontario, Canada, discusses the ongoing CoVasc-ICH (NCT05159219) trial, investigating colchicine as a preventative treatment for major cardiovascular events and brain injury in patients with intracerebral hemorrhage (ICH). Colchicine is an anti-inflammatory drug proven to be effective at reducing cardiovascular events in cardiology clinical trials and reducing hematoma size in preclinical ICH studies. This trial takes the novel approach of reducing inflammation to reduce the risk of further cardiovascular events following ICH. Within 48 hours of ICH symptom onset, patients will be randomized to receive colchicine or placebo, followed by close monitoring for one year. The trial is designed to assess the drug’s safety and efficacy, with particular attention to preventing hematoma expansion. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.